Document:

Master Supply Agreement

  
 Exhibit 10.33

  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 BERKELEY HEARTLAB, INC. AND DIADEXUS, INC. 

MASTER SUPPLY AGREEMENT 

 
 This Master Supply Agreement, dated as of
April 1, 2009, by and between diaDexus, Inc. (“diaDexus”) and Berkeley HeartLab, Inc. (“Lab”), sets forth the terms and conditions upon which diaDexus will sell to Lab, and Lab will purchase, various products (the
“Agreement”). The parties agree as follows: 
  

	A.	In consideration of Lab purchasing from diaDexus the products specified in the attached Product Addendum (“Products”) during the term of this Agreement,
diaDexus agrees to sell Products to Lab at the purchase prices set forth in the attached Product Exhibit. Lab shall use Products solely for performing in vitro clinical diagnostic testing on human blood samples (“Permitted Use”) solely
within its testing centers in the United States and its territories (the “Territory”). Lab shall not (i) transfer, offer to sell, sell or resell Products to any person or entity outside the Territory or (ii) establish warehouses,
testing centers or operation outlets outside the Territory for the Products. 

  

	B.	The parties hereto acknowledge that this Agreement, including the addenda and exhibits attached hereto and those documents listed in Section CC, sets forth the entire
agreement and understanding of the parties as to the subject matter hereof and supersedes all prior and contemporaneous discussions, agreements, and writings with respect hereto with respect to the subject matter hereof. Notwithstanding the
foregoing, the parties expressly acknowledge that the surviving obligations of the Master Supply Agreement and Business Associate Agreement by and between the parties hereto dated as of November 1, 2007 as well as any agreements by and between
Celera Corporation, and any agreements with other parties assigned to Celera Corporation, and diaDexus shall continue in full force and effect without regard to the signing of this Agreement. 

 

	C.	The term of the Agreement shall commence on April 1, 2009 and expire [*] (the “Term”), unless terminated earlier pursuant to Paragraph N or P.
Expiration or termination of this Agreement for any reason will not release a party from any obligation that has accrued prior to the effective date of such expiration or termination. Obligations relating to Utilization Reports and Net Sales
Reconciliation as set forth in the Product Addendum and Paragraphs B, C, E, J, Q, R, S, T, U, V, W, X, DD and FF shall survive expiration or termination of this Agreement. 

 

	D.	diaDexus shall ship Product(s) to Lab which orders such Product(s) under a purchase order and which is authorized by the parties under this Agreement. Invoices shall be
mailed to the following address: 

 Berkeley HeartLab, Inc. 

Accounts Payable Department 
 839 Mitten Road 
 Burlingame, CA 94010 

 

	E.	 Lab shall pay diaDexus within thirty (30) days after such invoice is received by Lab. [*]. All applicable sales or use taxes are the
responsibility of Lab. In those states where diaDexus collects local/state sales taxes, diaDexus will add these taxes to the invoices and after receipt of payment from Lab, diaDexus shall remit such amounts to the appropriate taxing authority(ies).
Any payment due and payable under the terms and conditions of this Agreement made after the date such payment is due and payable shall bear interest as of the 30th day after the date such payment was due and payable and shall continue to accrue such interest until such payment is
made at a rate equal to the lesser of the prime rate as reported by the Chase Manhattan Bank, New York, New York, on the date such payment is due, plus an additional one and one-half percent (1.5%), or the maximum rate permitted by law in the State
of California. All payments made under this Agreement shall be made in U.S. dollars, and such payments shall be made by check or wire transfer to one or more bank accounts to be designated in writing by diaDexus. If payments are not made, then
orders will be placed on credit hold. 

  

					
		 	Page 1 of 12	 	

  

	F.	Product shipment shall be made FOB diaDexus’ domestic supply source. Products will be shipped to the following address: 

Berkeley HeartLab, Inc. 
 960 Atlantic Ave, Suite #100 
 Alameda, CA 94501 

Attn: Lab Manager 
 510-263-4088 
  

	G.	Except as expressly provided herein, neither this Agreement nor any interest hereunder will be assignable, nor any other obligation delegable, by a party without the
prior written consent of the other, which shall not be unreasonably withheld or delayed; provided, however, that either party may assign this Agreement without consent to any successor in interest by way of merger or sale of all or substantially all
of its assets in a manner such that the assignor will remain liable and responsible for the performance and observance of all such party’s duties and obligations hereunder. Any purported assignments made in violation of this Paragraph G shall
be null and void. 

  

	H.	Notices and other communications permitted or required under this Agreement will be deemed to be properly given when received by the other party and if given in writing
and either delivered by hand, overnight delivery service, or mailed by First Class U.S. Mail, postage prepaid, addressed to the applicable party as follows: 

 

			
	diaDexus:	 	diaDexus, Inc.
		 	343 Oyster Point Boulevard
		 	South San Francisco, CA 94080-1913
		 	Attention: Patrick Plewman
		 	President and Chief Executive Officer
		
	Lab:	 	Berkeley HeartLab, Inc.
		 	960 Atlantic Avenue, Suite 100
		 	Alameda, CA 94501
		 	Attention: Vice President of Laboratory Operations
		
	With a copy to:	 	Berkeley HeartLab, Inc.
		 	839 Mitten Road
		 	Burlingame, CA 94010
		 	Attention: General Counsel

  

	I.	One month prior to the start of each calendar quarter, Lab will provide diaDexus with [*] forecast of orders for such quarter and [*]. Provided, however,
such [*] forecast shall only be a good faith projection of Lab’s expected utilization and shall not commit Lab to order the amount of Product set forth therein. 

Products shall be supplied in accordance with a specification for identity and quality of the Product as set forth in
the PLAC® Test product insert (the “Specification”). [*]. 

[*] 
 Lab
shall reasonably cooperate with diaDexus in the performance of periodic quality control surveys as requested by diaDexus to ensure that Products are used for the Permitted Use and meet regulatory requirements. Lab hereby agrees to discuss technical
performance and collaboratively resolve any problems with diaDexus technical support personnel, provided that all such personnel execute reasonable non-disclosure and non-use agreements, as may be requested by Lab. Lab shall de-identify all
information provided to diaDexus containing Protected Health Information (“PHI”) or electronic PHI. 
 diaDexus shall
provide competent trained personnel to assist Lab with Technical issues that may arise from time to time and to address technical issues associated with performance of the Product. 

 

	J.	Lab will provide diaDexus with monthly testing volume reports sorted by US Zip Code and international territories in the Snapshot Report and the Final Report. If
monthly testing volume sorted by US Zip Code and international territories is not reported, then Product orders will be placed on credit hold until monthly testing volume sorted by US Zip Code and international territories is reported.

  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
		 	Page 2 of 12	 	

  

	K.	This Agreement may not be amended or modified except by written agreement of both of the parties. 

 

	L.	diaDexus will not be liable for any failure to perform under this Agreement due to strikes, fire, earthquakes, explosion, flood, riot, lock-out, injunction,
interruption of transportation, unavoidable accidents, or inability to obtain supplies at reasonable prices. 

  

	M.	[*]. 

  

	N.	This Agreement may be terminated by Lab with or without cause at any time with ninety (90) days written notice. 

 

	O.	Items defined as Products listed on the Product Addendum or added on the Product Addendum by written amendment at a later date will have guaranteed pricing through the
Term of the Agreement. 

  

	P.	If any term of this Agreement is breached materially by either party and the parties cannot agree on a resolution, the non-breaching party may terminate this Agreement
if the breach is not cured within 30 days after notice is given in accordance with Paragraph H. 

  

	Q.	diaDexus represents and warrants to Lab that the Products supplied shall (i) not be adulterated or misbranded by diaDexus within the meaning of the U.S. Food,
Drug, and Cosmetic Act; (ii) be produced in accordance with the U.S. Food, Drug and Cosmetic Act Quality System Requirements, specifically 21 CFR Part 820; and (iii) function in accordance with the Specifications supplied by diaDexus in
connection with such Products after inspection and acceptance by Lab in accordance with Paragraph I; provided that Lab maintains and stores such Products in accordance with instructions contained in such documentation. diaDexus hereby
represents and warrants that, to the best of its knowledge, the practice of any technology or patents comprising the Product that are licensed hereunder is and will be free of any infringement of patents of other persons. EXCEPT AS SPECIFICALLY SET
FORTH IN THIS PARAGRAPH Q, DIADEXUS MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR USE, ANY WARRANTY OF
NON-INFRINGEMENT, ANY WARRANTY OF SAFETY, OR ANY OTHER STATUTORY WARRANTY. IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES INCURRED BY THE OTHER OR ANY AFFILIATE OR SUBSIDIARY
ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 

  

	R.	diaDexus agrees to defend, indemnify, and hold Lab, directors, officers, employees, and agents wholly harmless from and against third-party claims, losses, lawsuits,
settlements, demands, causes, judgments, expenses, and cost (including reasonable attorney fees) arising under or in connection with this Agreement (collectively, referred to as “Claims”) in the event that such Claims are caused by a)
diaDexus’ breach of any of its warranties in this Agreement, b) the failure of Products to function properly for the Permitted Use by Lab under this Agreement, c) any gross negligence or willful misconduct of diaDexus, or d) any other liability
resulting from Lab’s use of the Products within the Permitted Use under this Agreement. However, the foregoing rights to indemnity shall not apply to the extent that such Claims result from Lab’s negligence or willful misconduct,
including, without limitation, the negligence of Lab’s employees, or from the modification of any Product of diaDexus by Lab or a third party not within diaDexus’s control or without diaDexus’ express written permission. The
obligation of diaDexus to defend, indemnify and hold harmless shall also include, but is not limited to, any such third-party claims, losses, damages, lawsuits, settlements, demands, causes, judgments, expenses and costs (including reasonable
attorney fees) against Lab which relate in any manner to Lab’s alleged infringement of any property rights of a third party in or to the Product or licenses under this Agreement. 

Lab agrees to defend, indemnify, and hold diaDexus and subsidiaries, directors, officers, employees, and agents wholly harmless from and
against any and all Claims that arise from the willful misconduct of Lab including, without limitation, modification of any Product of diaDexus by Lab or a third party not within diaDexus’ control or without diaDexus’ express written
permission; Lab’s gross negligence or willful misconduct, including, without limitation, the gross negligence of Lab’s employees. However, the foregoing rights to indemnity shall not apply to the extent that such Claims result from
diaDexus’ negligence or willful misconduct including, without limitation, the negligence of diaDexus’ employees, or from the modification of any Product of Lab by diaDexus or a third party at diaDexus’ instruction. 

For purposes of this Paragraph R, the indemnified party shall give prompt written notice to the indemnifying party of any suits, claims,
or demands by third parties or the indemnified party that may give rise to any Claim for which indemnification may be required under this Paragraph R; provided, however, that failure to give such notice shall not relieve the
indemnifying party of its obligation to provide indemnification hereunder except if and to the extent that such failure materially affects the ability of the indemnifying party to defend the applicable Claim. 

 

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
		 	Page 3 of 12	 	

 The indemnifying party shall be entitled to assume the defense and control of any such Claim
at its own cost and expense; provided, however, that the indemnified party shall have the right to be represented by its own counsel at its own cost in such matters. In the event that the indemnifying party declines to or fails to
timely assume control of any such Claim, the indemnified party shall be entitled to assume such control, conduct the defense of, and settle such Claim, all at the sole cost and expense of the indemnifying party. 

Neither the indemnifying party nor the indemnified party shall settle or dispose of any Claim in any manner that would adversely affect
the rights or interests of the other party without the prior written consent of the other party, which shall not be unreasonably withheld or delayed. Each party shall cooperate with the other party and its counsel in the course of the defense of any
Claim, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses 
  

	S.	diaDexus shall, at its sole cost and expense, obtain and keep in force a policy of comprehensive general liability insurance with bodily injury, death, and property
damage limits of [*]. 

  

	T.	diaDexus acknowledges that Lab has a proprietary interest in its legal and business name and reputation. Lab acknowledges that diaDexus has a proprietary interest in
its legal and business name and reputation as well as the brand name and trademarks of its products. Therefore, each party agrees that it shall not use the other party’s name nor shall a party mention or describe this Agreement or its
relationship with the other party in any press release, advertising, marketing, and promotional materials or other publications or materials without first obtaining the prior written approval of the other party. Without limiting the foregoing,
diaDexus agrees not to use any name or mark of Lab or to quote the opinion of any of Lab’s employees in any advertising or other publicity, including in client lists or on diaDexus website, without obtaining the prior written consent of Lab.

  

	U.	 Lab shall label the Product as the PLAC® Test for Lp-PLA2, PLAC® Test, or Lp-PLA2 on its test requisition order forms. If
Lab wishes to market the diaDexus Product using the associated marks, diaDexus hereby grants to Lab a non-exclusive, non-sublicensible license to use its trademarks solely for the Permitted use. 

 

	V.	[*]. 

  

	W.	The parties have provided to each other prior to entering into this Agreement, and in connection with this Agreement may in the future provide to each other,
confidential information, including but not limited to each party’s know-how, inventions, improvements, discoveries, patent applications, trade secrets, devices, compositions, formulas, ideas, designs, drawings, specifications, techniques,
data, computer programs, processes, customer lists, product prices, discounts, sales data, marketing, product development and other business plans, legal affairs and financial and technical information and material embodiments thereof (collectively,
the “Confidential Information”). The terms and conditions of this Agreement shall be Confidential Information of the parties, and subject to the terms of this Paragraph W. 

The receiving party shall maintain the Confidential Information of the disclosing party in confidence, shall not disclose such
Confidential Information to any third party, and shall not use such Confidential Information for any purpose except as expressly permitted under the terms and conditions of this Agreement. Notwithstanding the previous sentence, the receiving party
may disclose the Confidential Information of the disclosing party to its employees, agents, consultants, and professional, scientific, medical, and legal advisors who have a need to know such Confidential Information; provided that any such
person to whom disclosure is made is bound by obligations of non-disclosure and non-use no less restrictive then those set forth herein. The receiving party shall take the same degree of care that such party uses to protect its own confidential and
proprietary information of a similar nature and importance, but in no event shall such care be less than reasonable care. 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
		 	Page 4 of 12	 	

  
 The obligations of
non-disclosure and non-use under this Paragraph W will not apply as to particular Confidential Information of a disclosing party to the extent that such Confidential Information: (a) is at the time of receipt, or thereafter becomes,
through no fault of the receiving party, published or publicly known or available; (b) is known by the receiving party at the time of receiving such information, as evidenced by written records; (c) is hereafter furnished to the receiving
party by a third party without breach of a duty to the disclosing party; or (d) is independently discovered or developed by the receiving party without use of, application of, access to, or reference to Confidential Information of the
disclosing party as evidenced by written records. Both parties shall not, directly or indirectly, (a) use the Confidential Information to guide or aid a search and/or evaluation of publicly available information for purposes of either showing
the Confidential Information is in the public domain or to recreate the knowledge or logic contained within the Confidential Information from non-protected sources and/or (b) disassemble, reverse engineer or otherwise use the Confidential
Information as a guide or template to otherwise recreate the logic or knowledge contained within the Confidential Information and/or to directly or indirectly offer or use a product and/or service that incorporates or uses the functionality of
anything disclosed in the Confidential Information or substantially equivalent to or substituting for, any functionality disclosed by the other party in the Confidential Information of such other party or for any other purpose. 

Disclosure of Confidential Information shall not be precluded if such disclosure (i) is in response to a valid order of a court or
other governmental body or (ii) is required by law or regulation; provided, however, that the receiving party shall first have given reasonable prior notice to the disclosing party and shall have made a reasonable effort to obtain
a protective order, or to cooperate with the disclosing party’s efforts, as applicable, to obtain a protective order limiting the extent of such disclosure and requiring that the Confidential Information so disclosed be used only for the
purposes for which such order was issued or as required by such law or regulation. 
 The receiving party agrees that its
obligations under this Paragraph W are necessary and reasonable to protect the disclosing party’s business interests and that the unauthorized disclosure or use of Confidential Information of a disclosing party will cause irreparable harm
and significant injury, the degree of which may be difficult to ascertain. The receiving party further acknowledges and agrees that in the event of any actual or threatened breach of this Paragraph W, the disclosing party may have no adequate
remedy at law and, accordingly, that the disclosing party will have the right to seek an immediate injunction enjoining any breach or threatened breach of this Paragraph W, as well as the right to pursue any and all other rights and remedies
available at law or in equity for such breach or threatened breach. 
 All obligations of non-disclosure and non-use imposed
pursuant to the terms and conditions of this Paragraph W shall survive expiration or termination of this Agreement and continue in full force and effect for a period of ten (10) years after the effective date of such expiration or such
termination. 
 Notwithstanding the foregoing, if a party determines that it is required by applicable law to
publicly file, register or notify this Agreement with a governmental authority, including public filings pursuant to securities laws, it will provide the proposed redacted form of the Agreement to the other party with a reasonable amount of time for
the other party to review such draft and agree upon such redacted form of the Agreement. Such party shall not unreasonably withhold or delay providing such consent. The party making such filing, registration or notification will request, and use
commercially reasonable efforts to obtain, confidential treatment of all terms redacted from this Agreement for a term of at least five years. Each party will be responsible for its own legal and other external costs in connection with any such
filing, registration or notification. 
  

	X.	This Agreement is made in accordance with, and this Agreement and any dispute arising out of, related to, or in connection with this Agreement shall be governed and
construed under, the laws of the State of California, United States of America, without giving effect to any choice of law principles that would result in the application of the laws of any State other than the State of California. If any claim,
dispute, or controversy arising out of or in connection with this Agreement or the breach or alleged breach of this Agreement is not resolved by informal discussion of the parties within thirty (30) business days after each party is notified of
such dispute, the dispute shall be referred to the CEOs of each party. Upon such referral, these two individuals shall undertake good faith discussions, and shall be empowered to reach a prompt, final resolution of the issue that shall be binding
upon both parties. If these two individuals do not resolve the dispute within thirty (30) days after such referral, and the parties do not mutually agree in writing to extend such resolution period, the matter may be submitted for adjudication
to the United States District Court, Northern District of California, or in the event that subject matter jurisdiction does not exist in such Court, to the state court sitting within the territory of the Northern District of California. Each party
hereby consents to personal jurisdiction and venue in these courts. Nothing in this Agreement shall be deemed as preventing either party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the
parties and the subject matter of the dispute as necessary to protect either party’s name, proprietary information, trade secret, know-how or any other proprietary right. 

 

	Y.	The relationship of the parties established by this Agreement is that of independent contractors. Nothing in this Agreement shall be constructed to create any other
relationship between the parties. Neither party shall have any right, power, or authority to bind the other or assume, create, or incur any expense, liability, or obligation, express or implied, on behalf of the other party. This Agreement is
neither expressly nor impliedly made for the benefit of any party other than those executing it. 

  

					
		 	Page 5 of 12	 	

  

	Z.	The failure of a party to enforce any rights or provisions of the Agreement shall not be construed to be a waiver of such rights or provisions, or a waiver by such
party to thereafter enforce such rights or provision or any other rights or provisions hereunder. No trade customs, courses of dealing or courses of performance by the parties shall be relevant to modify, supplement, or explain any term(s) used in
this Agreement. 

  

	AA.	If any term, condition or provision of this Agreement is held to be unenforceable for any reason, it shall be interpreted to achieve the intent of the parties to this
Agreement to the extent possible rather than voided. In any event, all other terms, conditions, and provisions of this Agreement shall be deemed valid and enforceable to the full extent. 

 

	BB.	Each party shall carry out its activities pursuant to this Agreement in compliance with all applicable federal, state, and local laws, rules, regulations, and
guidelines. 

  

	CC.	Upon the execution of this Agreement, diaDexus shall simultaneously execute a Business Associate Agreement with Lab in a form substantially similar to the ones attached
hereto as Exhibit A. 

  

	DD.	This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.

  

	EE.	To the extent that there is any conflict or inconsistency between this Agreement and any purchase order, the attached Product Addendum, or any other document pertaining
to the supply of Product, the terms of this Agreement shall govern unless specifically acknowledged and agreed to in writing by each of the parties. 

  

	FF.	 Each party to this Agreement represents that (i) it has not been convicted of a criminal offense related to health care, or (ii) is not
currently listed by a federal agency as debarred, excluded or otherwise ineligible for participation in federally funded health care programs. Either party will notify the other in writing within five days of any change in this representation or if
circumstances change to render this representation false during the term of this Agreement. Such change in circumstances will constitute cause by the other party to immediately terminate this Agreement. For purposes of this paragraph, a party is
defined as the entities entering into this contract, and/or its principals, directors and officers. 

  

											
	Berkeley HeartLab, Inc.	 	diaDexus, Inc.	 	
						
	By:	 	 /s/ Kathy Ordoñez
	 		 	By:	 	 /s/ Patrick Plewman
	 	
				
	 Kathy Ordoñez
	 		 	 Patrick Plewman
	 	
	Title:	 	CEO	 		 	Title:	 	President & CEO	 	
						
	Date:	 	April     , 2009	 		 	Date:	 	April 17th, 2009	 	

  

					
		 	Page 6 of 12	 	

  
 diaDexus - Berkeley
HeartLab, Inc. 
 PRODUCT ADDENDUM 
 PRODUCT EXHIBIT 
  

					
	 Catalog #
	  	 Description
	  	 Lab Price

	90116	  	 PLAC® Test Kit for Hitachi Series Analyzers
 250
Test Kit for Hitachi, Roche Hitachi Modular P
 Automated Clinical Chemistry Analyzers
	  	[*]
			
	90108	  	 PLAC® Calibrator Kit
 for Automated Clinical
Chemistry Analyzers
	  	[*]
			
	90109	  	 PLAC® Control Kit
 for Automated Clinical Chemistry
Analyzers
	  	[*]

 [*]

 

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
		 	Page 7 of 12	 	

  
 EXHIBIT A

 diaDexus- Berkeley Heart Lab, Inc. 
 Business Associate Agreement 
 This Business Associate
Agreement (“Agreement”) is entered into this 1st
day of April 2009 (the “Effective Date”) by and between Berkeley HeartLab, Inc., a California corporation (“BHL”), and diaDexus, Inc., a Delaware corporation (“Contractor”). 

RECITALS 
 A.
Pursuant to HIPAA, BHL, as a Covered Entity, as defined in 45 C.F.R. §160.103, is required to enter into this Agreement to obtain satisfactory assurances that Contractor, a Business Associate, will appropriately safeguard all Protected Health
Information disclosed, created or received by Contractor on behalf of, BHL. 
 B. BHL desires to engage Contractor to perform
certain functions for, or on behalf of, BHL involving (i) supply of products for the creation or use of PHI by BHL and (ii) the possible disclosure of PHI by BHL to Contractor, or the creation or use of PHI by Contractor on behalf of BHL,
and Contractor desires to perform such functions. 
 C. This contract shall be deemed an amendment to the parties’ Master
Supply Agreement dated April 1, 2009 (“Underlying Agreement”). 
 In consideration of the mutual
promises below and the exchange of information pursuant to this Agreement and in order to comply with all legal requirements for the protection of this information, the parties therefore agree as follows: 

Article I. Definitions of Terms 
 1.01 Business Associate shall have the meaning given to such term in 45 C.F.R. §160.103. 
 1.02 C.F.R. shall mean the Code of Federal Regulations. All references to the C.F.R. are to their then current version. 
 1.03 Designated Record Set shall have the meaning given to such term in 45 C.F.R. §164.501. 
 1.04 ePHI shall mean electronically created, received, maintained or transmitted PHI. 
 1.05 HIPAA shall mean the Health Information Portability and Accountability Act of 1996, as amended from time to time. 
 1.06 Privacy Laws shall mean HIPAA, the HIPAA regulations and any other applicable state or federal laws or regulations affecting or regulating the privacy and/or security of health information (65
Fed. Reg. 82462-82829 (December 28, 2000 and as amended on August 14, 2002 in 67 Fed Reg. 53,182-53273 (Part 160 and 164).)). 
 1.07 Protected Health Information (“PHI”) shall have the meaning given to such term in 45 C.F.R. §164.501 and other applicable state Privacy Laws. 

1.08 “Required by Law” shall have the meaning given to such phrase in 45 C.F.R. §164.501. 

1.09 Security Rule shall have the meaning given such term in 45 C.F.R. § 164.302-164.318. 

  

					
		 	Page 8 of 12	 	

  
 Article II.
Obligations of Contractor 
 2.01 HIPAA Obligations. Contractor acknowledges that federal regulations relating to
the confidentiality of PHI requires Covered Entities and Business Associates to comply with HIPAA. HIPAA requires BHL to ensure that Business Associates who receive confidential information in the course of providing services on behalf of BHL comply
with certain HIPAA obligations regarding the confidentiality of PHI. Accordingly, Contractor shall only use and/or disclose PHI in a manner consistent with this Agreement, the Underlying Agreement, the Privacy Rule, the Security Rule or as Required
by Law and only in connection with providing services hereunder. 
 2.02 Permitted Uses and Disclosures. In connection
with the services provided by Contractor to BHL, Contractor may not use or disclose PHI received or created pursuant to this Agreement as set forth in this Section 2. Contractor shall maintain appropriate safeguards to ensure that PHI is not
used or disclosed other than as provided by this Agreement or as required by Law. Except as may be limited by this Agreement, Contractor may use or disclose PHI it obtains or creates in its capacity as Contractor for the proper management and
administration of the Contractor, to carry out Contractor’s legal responsibilities under the Underlying Agreement and this Agreement; provided that any disclosures are Required by Law. Contractor shall, if it makes a disclosure as permitted
hereunder, (i) provide training to members of Contractor’s workforce regarding the confidentiality requirements in the Privacy Laws, the Security Rule and this Agreement; and (ii) obtain reasonable assurances from the person to whom
the information is disclosed that it will remain confidential and used or further disclosed only for the purpose for which it was disclosed to such person and in accordance with the Privacy Laws, and such person will notify Contractor of any
instances of which it is aware in which the confidentiality of such PHI has been breached. Further, Contractor shall ensure that any use or disclosure of PHI are subject to the principle of “minimum necessary use and disclosure,” i.e.,
only the PHI that is the minimum necessary to accomplish the intended purpose of the use, disclosure, or request may be disclosed. Notwithstanding anything to the contrary in this Agreement, Contractor may use PHI to report violations of law to
appropriate federal and state authorities, consistent with 45 C.F.R. §164.502(j)(1), but only to the extent such reports are required by Law and provided that (a) a copy of each such report is provided to BHL and (b) a complete and
accurate summary of any oral disclosure is provided to BHL. 
 Contractor shall require the recipient of any PHI to agree to the
same restrictions and conditions that apply to Contractor under this Agreement as to the PHI, unless BHL agrees to the contrary in writing with respect to a specific release of information. 

2.03 Withdrawal of Authorization. If the use or disclosure of PHI in this Agreement is based upon an individual’s specific
authorization for the use of his or her PHI, and such individual revokes such authorization in writing, or the effective date of such authorization has expired, or the authorization is found to be defective in any manner that renders it invalid, BHL
shall notify Contractor of such revocation, expiration or defect in the authorization and thereafter, Contractor shall cease the use and disclosure of any such individual’s PHI except to the extent it has relied on such use or disclosure, or
where an exception under the Privacy Laws expressly applies. 
 2.04 ePHI Security. Contractor shall do all the
following: 
 (a) Implement administrative, physical and technical safeguards that reasonably and appropriately
protect the confidentiality, security, integrity and availability of ePHI that Contractor creates, receives, maintains or transmits on behalf of BHL, which in any event shall be no less than the HIPAA-related implementation recommendations of
the NIST/URAC/WEDI Health Care Security Workgroup (see www.wedi.org; keyword search “NIST” or “URAC”) ; 
 (b) Ensure that any agent, including a subcontractor, to whom Contractor provides ePHI agrees in writing to implement reasonable and appropriate safeguards to protect ePHI; and 

  

					
		 	Page 9 of 12	 	

  
 (c)
Upon request, make available to BHL Contractor’s documented information security program, including the most recent ePHI risk analysis, policies, procedures, security incidents and responses, and evidence of training. 

2.05 Access to PHI by Individuals. Contractor shall cooperate with BHL to fulfill all requests by individuals for access to the
individual’s PHI in a Designated Record Set that are approved by BHL. Contractor shall cooperate with BHL in all respects necessary for BHL to comply with applicable Privacy Laws. Because California law requires that copies of requested records
be forwarded to patients within fifteen (15) days of their request, Contractor agrees to forward any copies requested by BHL for this purpose within 5 business days. If Contractor receives a request from an individual for access to PHI,
Contractor promptly shall forward such request to BHL and await BHL’s instructions with respect to denial or approval of such request. BHL shall be solely responsible for determining the scope of PHI and Designated Record Set with respect to
each request by an individual for access to PHI. Upon instruction from BHL, Contractor shall deny such individual’s request or fulfill such individual’s request by providing such individual’s PHI to such individual. BHL shall
reimburse Contractor a portion of the fee charged by BHL to the individual that is proportional to the amount of PHI produced by Contractor in relation to the amount of PHI produced by BHL, less reasonable BHL administrative expenses. 

2.06 Amendment of PHI. As directed and in accordance with the time frames reasonably specified by BHL, Contractor shall
incorporate all amendments or addenda to PHI received from BHL, pursuant to 45 C.F.R. §164.526 and similar applicable Privacy Laws. Within ten (10) business days following Contractor’s amendment of PHI as directed by BHL,
Contractor shall provide written notice to BHL confirming that Contractor has made the amendments or addenda to PHI as directed by BHL and containing any other information as may be necessary for BHL to provide adequate notice to the individual in
accordance with 45 C.F.R. §164.526 and similar applicable Privacy Laws. 
 2.07. Disclosure Accounting. In the event
that Contractor makes any disclosures of PHI that are subject to the accounting requirements of 45 C.F.R. §164.528, Contractor promptly shall report such disclosures to BHL. The notice by Contractor to BHL of the disclosure shall include the
name of the individual, the recipient, and the reason for disclosure, and the date of the disclosure. Contractor shall maintain a record of each such disclosure, including the date of the disclosure, the name and, if available, the address of the
recipient of the PHI, a brief description of the PHI disclosed and a brief description of the purpose of the disclosure. Contractor shall maintain this record for a period of six (6) years and make available to BHL upon request in an electronic
format so that BHL may meet its disclosure accounting obligations under 45 C.F.R. §164.528. 
 2.08 Reporting and
Mitigating Unauthorized Uses and Disclosures of PHI. Promptly following its notice of the same, Contractor shall report to BHL any uses, disclosures or risks of disclosure of PHI not authorized by this Agreement of which it becomes aware and,
with respect to ePHI, any security incident, including any attempted or successful unauthorized access, use, disclosure, modification, or destruction of ePHI or interference with information system operations all as required by
applicable Privacy Laws and applicable state identity theft laws (e.g., Cal. Civ. Code §1798.82). Contractor agrees to mitigate, to the extent practicable, the deleterious effects of any use or disclosure of PHI not authorized by this
Agreement. 
 2.09 Ownership of Information. As between Contractor and BHL, all PHI and ePHI shall be deemed owned
by BHL unless otherwise agreed in writing by BHL. During the term of this Agreement, Contractor and any authorized subcontractors shall have the right to use the PHI and ePHI solely for the purposes of this Agreement. Contractor and its
agents shall not have the right to de-identify the PHI and/or ePHI unless agreed in writing by BHL. 
 2.10 Internal
Practices, Books, and Records. Contractor shall make available its internal practices, books, and records relating to the use and disclosure of PHI received from, created, or received by Contractor on behalf of BHL to the U.S. Department of
Heath and Human Services or his designee for the purpose of determining BHL’s compliance with 45 C.F.R. pt. 160 and 164, subparts A and E and amendments thereto. 

  

					
		 	Page 10 of 12	 	

  
 2.11 BHL’s Obligations.

 (a) BHL shall notify Contractor of any limitation(s) in its notice of privacy practices of BHL in accordance with 45 C.F.R.
§ 164.520, to the extent that such limitation may affect Contractor’s use or disclosure of PHI. 
 (b) BHL shall notify
Contractor of any changes in, or revocation of, permission by individual to use or disclose PHI, to the extent that such changes may affect Contractor’s use or disclosure of PHI. 

(c) BHL shall notify Contractor of any restriction to the use or disclosure of PHI that BHL has agreed to in accordance with 45 C.F.R.
§ 164.522, to the extent that such restriction may affect Contractor’s use or disclosure of such PHI. 
 2.12 Permitted Requests
from BHL. BHL shall not request Contractor to use or disclose PHI in any manner that would not be permissible under the Privacy Rule if done by BHL. 
 Article III. Term and Termination 
 3.01 Term. This Agreement shall
commence the Effective Date and end upon the earlier of (i) expiration or termination of the Underlying Agreement or (ii) when one party notifies the other party of its intent to terminate pursuant to Section 3.02. 

3.02 Termination. Either party to this Agreement may terminate the Agreement upon provision of thirty (30) days’ prior
written notice. 
 3.03 Effects of Termination; Disposal of PHI and/or ePHI. Upon termination of this Agreement,
Contractor shall return to BHL or destroy all PHI and/or ePHI that Contractor obtained or maintained pursuant to this Agreement on behalf of BHL, including the PHI and/or ePHI in the possession of any of Contractor’s agents or
affiliates. If the parties determine that returning or destroying the PHI is infeasible, Contractor shall provide to BHL notification of the specific conditions that make return or destruction infeasible. Contractor shall extend the protections
provided under this Agreement to such PHI and/or ePHI, and limit further use or disclosure of such PHI and/or ePHI to those purposes that make the return or destruction of the PHI and/or ePHI infeasible. Contractor shall require
that its agents, affiliates, subsidiaries and subcontractors agree to the extension of all protections, limitations and restrictions required of Contractor hereunder to the extent such agents, affiliates, subsidiaries or subcontractors are in
possession of such PHI and/or ePHI. This Section 3.03 shall survive the termination of this Agreement. 
 Article IV.
Miscellaneous 
 4.01 Notices. Any notice required to be given pursuant to the terms and provisions of this
Agreement shall be in writing and may be either personally delivered, sent by commercial; overnight delivery service or sent by registered or certified mail in the United States Postal Service, Return Receipt Requested, postage prepaid, addressed to
each party at the addresses which follow or to such other addresses as the parties may hereinafter designate in writing: 
  

					
	BHL:	  	839 Mitten Road
		  	Burlingame, CA 94010
		  	Attn:	 	General Counsel

  

					
		 	Page 11 of 12	 	

					
	Contractor:	  	diaDexus, Inc.
		  	343 Oyster Point Boulevard
		  	South San Francisco, CA 94080-1913
		  	Attn:	 	Patrick Plewman
		  		 	Chief Executive Officer

 Any such notice
shall be deemed to have been given, if mailed as provided herein, as of the date received. 
 4.02 Amendments. This
Agreement may, from time to time, be modified or amended in writing and such written modifications are signed by both parties to this Agreement. 
 4.03 Counterparts. This Agreement may be executed in counterparts, any of which is considered to be an original agreement. 
 4.04 Assignment/Subcontracting. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective legal representatives, successors and assigns. Neither party
may assign the rights or obligations under this Agreement without the express written consent of the other party; provided, however, that either party may assign this Agreement without such consent to any permitted assignee of such party’s
rights and obligations under the Underlying Agreement. 
 4.05 Construction. This Agreement shall be construed as broadly
as necessary to implement and comply with the HIPAA regulations. The parties agree that any ambiguity in this Agreement shall be resolved in favor of a meaning that complies and is consistent with the HIPAA regulations. 

IN WITNESS WHEREOF, the parties hereto have duly executed this agreement to be effective as of the date of the Underlying
Agreement. 
  

									
	BHL	 		 	CONTRACTOR
			
	 /s/ Kathy Ordoñez
	 		 	 /s/ Patrick Plewman

	 Kathy Ordoñez
	 		 	 Patrick Plewman

					
	Title:	 	CEO	 		 	Title:	 	Chief Executive Officer
					
	Date:	 	April     , 2009	 		 	Date:	 	April 17th, 2009

  

					
		 	Page 12 of 12Addendum No. 1 to the BHL Master Supply Agreement

  
 Exhibit 10.34

  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 Addendum No. 1 to the Master Supply Agreement Dated as of
April 1, 2009 
 This Addendum No.1 to the Master Supply Agreement dated as of April 1, 2009 (the
“Addendum”) is effective as of April 1, 2010 (the “Addendum Effective Date”), by and between diaDexus, Inc. (“diaDexus”), and Berkeley HeartLab, Inc. (“Lab”). 

WHEREAS, Lab and diaDexus are parties to that certain Master Supply Agreement dated April 1, 2009 (the “Agreement”);

 WHEREAS, the parties desire to amend such Agreement to extend the term of the Agreement, make other changes to the Agreement.

 NOW THEREFORE, in consideration of the agreements, mutual representations and covenants contained herein and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 

1. Definitions. All capitalized terms not defined herein shall have the meaning assigned to them in the Agreement. Notwithstanding
the foregoing, any reference to “Product Addendum” in the Agreement shall be amended to read “Amended Product Addendum” as defined in Section 3 of this Addendum. 

2. Term. Section C of the Agreement is hereby deleted in its entirety and replaced with the following: 

The term of the Agreement shall commence on April 1, 2009 and expire [*] (the “Term”), unless
terminated earlier pursuant to Paragraph N or P. Expiration or termination of this Agreement for any reason will not release a party from any obligation that has accrued prior to the effective date of such expiration or termination. Obligations set
forth in the Amended Product Addendum and Paragraphs B, C, E, J, Q, R, S, T, U, V, W, X, DD and FF shall survive expiration or termination of this Agreement. 
 3. Monthly Testing Volume Reports. The first sentence of Section J of the Agreement is hereby deleted in its entirety and replaced with the following: 

Lab will provide diaDexus with monthly testing volume reports sorted by US Zip Code and international territories in the Final Report.

 4. Product Addendum. The Product Addendum attached to the Agreement shall be deleted in its entirety and replaced with
the Amended Product Addendum attached hereto and incorporated herein. [*] 
 5. Entire Agreement. In the event of
any conflict between the terms and conditions of this Addendum and the Agreement, the terms and conditions of this Addendum shall control. Except as otherwise provided in the Addendum, the parties agree that all provisions of the Agreement are
hereby ratified and agreed to be in full force and effect and are incorporated herein by reference. This Addendum and the Agreement (as amended hereby), including without limitation all Attachments hereto, contain the entire agreement among the
parties relating to the subject matter herein and all prior proposals, discussions and writings by and among the parties and relating to the subject matter herein, whether written or oral, are superseded hereby and thereby. None of the terms of this
Addendum shall be deemed to be amended unless such Addendum is in writing, signed by all parties hereto, and recites specifically that it is an addendum to the terms of this Addendum. 

  

					
	Confidential	 	Page 1	 	

  
 IN WITNESS WHEREOF,
the parties hereto have caused this Addendum to be executed by their fully authorized representatives. 
  

					
	diaDexus, Inc.:	 		 	 Berkeley HeartLab, Inc.:

			
	 By: /s/ Patrick Plewman
	 		 	 By: /s/ Jonathan Wolin

			
	 Name: Patrick Plewman
	 		 	 Name: Jonathan Wolin

			
	 Title: President and CEO
	 		 	 Title: Secretary

			
	 Date: March 31, 2010
	 		 	 Date: March 31, 2010

 

							
		 	Approved as to legal form for BHL:	 	/s/ Victor K. Lee                    	  	
		 		 	Victor K. Lee (March 31, 2010)

  

					
	Confidential	 	Page 2	 	

  

					
		 	diaDexus - Berkeley HeartLab, Inc.	 	
		 	AMENDED PRODUCT ADDENDUM	 	

 PRODUCT EXHIBIT 

 

					
	 Catalog #
	  	 Description
	  	 Lab Price

	90116	  	 PLAC® Test Kit for Hitachi Series

Analyzers
 250 Test
Kit for Hitachi, Roche Hitachi
 Modular P
 Automated Clinical Chemistry Analyzers
	  	[*]
			
	90108	  	 PLAC® Calibrator Kit
 for Automated Clinical
Chemistry Analyzers
	  	[*]
			
	90109	  	 PLAC® Control Kit
 for Automated Clinical Chemistry
Analyzers
	  	[*]

 [*] 

 

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

					
	Confidential	 	Page 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]